Latest Conference Coverage

Global R&D leaders discuss the need for collaboration in medical research and how regulatory agencies are working to create the proper environment for advancements.

Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically significant event-free survival in a Phase III trial for resectable gastric and gastroesophageal junction cancers, signaling a potential shift in standard perioperative care.

In the Phase III IMforte trial, Tecentriq (atezolizumab) and Zepzelca (lurbinectedin) reduced the risk of disease progression or death by 46% as a first-line maintenance therapy for patients with extensive-stage small cell lung cancer.

Phase III data presented at ASCO 2025 and published in The New England Journal of Medicine show that Pfizer’s Braftovi (encorafenib), combined with Erbitux (cetuximab) and mFOLFOX6, significantly improves overall survival and progression-free survival in treatment-naïve patients with BRAF V600E-mutant metastatic colorectal cancer—potentially establishing a new first-line standard-of-care for this high-risk population.

In the DESTINY-Breast09 study, Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% in patients with HER2-positive metastatic breast cancer.

This year’s conference highlighted a number of critical areas in clinical R&D including financial management, representation, and eCOA.

Discover how evolving clinical trial trends are reshaping patient and site experiences—and the steps sponsors can take to stay ahead—in this conversation with uMotif CEO Steve Rosenberg at SCOPE Summit 2025.

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Shakthi Kumar, chief strategy & business officer, Edetek, provides examples of how Agentic AI can accelerate clinical development.

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Graham Clark, CEO, Phastar, discusses key objectives for attending SCOPE, the rise of real-world evidence, and partnerships critical to improving the success of clinical trial outcomes.

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Samuel Salvaggio Senior Trial Design Lead, One2Treat, discusses partnerships that remain vital for guaranteeing success in clinical trial efficiency.

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Samuel Salvaggio, Senior Trial Design Lead, One2Treat, discusses the company's main goals for attending the SCOPE Summit, including patient centric trial design.

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Rajneesh Patil, vice president, digital innovation, IQVIA, highlights the impact of artificial intelligence/machine learning in improving outcomes and maintaining safety with its implementation.

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Drew Garty, chief technology officer, clinical data, Veeva Systems, discusses clinical data trends for 2025 and simplifying management processes.

Sepehr Shojaei, VP of Design Solutions at Lightship, talks about how the company works with pharma and contract research organization (CRO) partners to support clinical trials that are patient-first and accessible.

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Pamela Tenaerts, chief scientific officer, Medable, discusses the need for more data around the implementation of clinical technology.

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Shakthi Kumar, chief strategy & business officer, Edetek, discusses how Edetek's R&D cloud system addresses challenges in clinical data management.

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Jonathan Norman, director, localization services, YPrime, discusses the importance of communicating with patients in their native languages.

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Richard Young, chief strategy officer, Cluepoints, offers his key takeaways from this year's SCOPE Summit in Orlando.

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Peter Ronco, CEO, Emmes, provides advice to small biopharma companies looking to scale their clinical programs without overextending resources.

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Richard Young, chief strategy officer, CluePoints, discusses goals of the SCOPE Summit and CluePoints' evolving approach to risk detection.

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Patil, vice president, digital innovation, IQVIA, discusses how artificial intelligence/machine learning can help in areas such as feasibility, site selection, and patient recruitment.

Session explores innovation in operationalizing clinical trials and how challenges with adoption can be addressed.

In an interview with Applied Clinical Trials Associate Editor Don Tracy Peter Ronco, CEO, Emmes, discusses the number of risks small biopharma companies taken when taking on clinical trial partners/

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Garty, chief technology officer, clinical data, provided his key takeaways from a panel he participated in on the growing interest around pragmatic studies.

Conference breakout session explores strategies for trial sites to strengthen patient relationships.

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Tenaerts, chief scientific officer, Medable, highlights the recent findings and how decentralized elements can improve access to underrepresented populations.

In an interview with ACT Associate Editor Don Tracy, Peter Ronco, CEO, Emmes, discusses the "Choosing the Right Allies: Ensuring Clinical Trial Success for Small Biopharma" session.